ClinicalTrials.gg
DrugBiologicalRead study by study

Ianalumab clinical trials

Also written VAY736.

studies test it
34
open now
5
in phase 3
13
first study started
2010
ClinicalTrials.gov finds 35 studies for ianalumab. How that becomes 34 here

Every study that search finds has been read, to see whether and how it gives ianalumab. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count

  1. 35Found by its intervention search · See all 35 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 26 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. 35Give ianalumab to participants
  3. −1Observe patients on it, or give it outside a trial
  4. 34Test it: the count on this site

Get an email when these change. Save the ianalumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Ianalumab
23

Development codes

VAY736
31

Studies by the year they started

33 studies that test it; most in 2022 (6); 1 more planned to start later

Studies that test ianalumab, by start year
YearStudies
20101
20121
20132
20141
20151
20172
20184
20191
20226
20236
20244
20251
20263

Who runs them

Industry 34 · Other 0

Novartis Pharmaceuticals (34)

Often tested with

Tested in the same studies.

Iscalimab (2) · LYS-006 (1) · Arumakimig (1) · Remibrutinib (1) · Eltrombopag (1) · Thrombopoietin Receptor Agonist (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 4, 3 in phase 3

Studies that test ianalumab, phase 3 first.

Studies

Open first, then newest update. How each study uses ianalumab has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 34

See all 34 studies that test ianalumab →

Tested on its own · 25 — no other medicine in its arm

Showing 20 of 25. See all 25 →

Tested with established drugs · 5 — they are given beside it
Tested in a combination · 4 — another drug in the study is under test too
Observed · 1 — patients on it are followed, or it is given outside a trial

Codes

What other systems call ianalumab · ClinicalTrials.gg INT001242

  • MeSH (NLM) C000656267ianalumabConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) ZN2GQ3II96IANALUMABConfirmed FDA, NLM
  • NCI Thesaurus C116788IanalumabOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion